| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 32.44 | 171 |
| Intrinsic value (DCF) | 5.82 | -51 |
| Graham-Dodd Method | 1.91 | -84 |
| Graham Formula | 25.44 | 113 |
GuiZhou SanLi Pharmaceutical Co., Ltd. is a prominent Chinese pharmaceutical company established in 1995 and headquartered in Guiyang. Specializing in the research, development, production, and marketing of a diverse portfolio of medicines, SanLi serves critical healthcare segments including pediatric care, respiratory health, and cardiovascular diseases. The company has built a robust presence in China's rapidly growing biotechnology and healthcare sector, leveraging its long-standing expertise to address essential medical needs. With a product range that also encompasses digestive, trauma injury, rehabilitation, and ophthalmic medicines, SanLi demonstrates a strategic focus on high-demand therapeutic areas. As a publicly traded entity on the Shanghai Stock Exchange, the company plays a significant role in China's domestic pharmaceutical supply chain, contributing to healthcare accessibility and innovation. Its integrated business model from R&D to commercialization positions it as a key player in the regional healthcare landscape, catering to both chronic and acute medical conditions across diverse patient demographics.
GuiZhou SanLi Pharmaceutical presents a mixed investment profile with moderate growth potential tempered by financial constraints. The company generated CNY 2.14 billion in revenue with a healthy net income of CNY 274 million, translating to a diluted EPS of CNY 0.67 and a dividend yield supported by a CNY 0.34 per share payout. However, concerning indicators include weak operating cash flow of CNY 107 million relative to earnings, significant total debt of CNY 561 million that exceeds cash reserves of CNY 475 million, and substantial capital expenditures. The beta of 0.704 suggests lower volatility than the broader market, which may appeal to risk-averse investors in the healthcare sector. The primary investment appeal lies in SanLi's established market position in specialized pharmaceutical segments and China's growing healthcare demands, though investors should carefully monitor the company's debt management and cash flow generation capabilities.
GuiZhou SanLi Pharmaceutical operates in the highly competitive Chinese pharmaceutical market, where its competitive positioning is defined by several key factors. The company's primary advantage lies in its diversified product portfolio spanning multiple therapeutic areas, particularly its strength in pediatric medications which represents a specialized and less crowded niche compared to broader pharmaceutical markets. This diversification provides revenue stability across different medical segments. SanLi's nearly three-decade presence in the industry has established brand recognition and distribution networks within China's complex healthcare system. However, the company faces intense competition from both domestic pharmaceutical giants and international players with greater R&D capabilities and financial resources. The moderate market capitalization of approximately CNY 5.26 billion positions SanLi as a mid-tier player rather than an industry leader. The company's competitive challenges include limited scale compared to larger competitors, potentially constraining its ability to invest in innovative drug development. Its focus on established therapeutic areas rather than cutting-edge biologics or novel drug discovery may limit growth prospects but provides stability in traditional markets. The debt level exceeding cash reserves could hinder aggressive expansion or R&D initiatives compared to better-capitalized competitors. SanLi's regional focus within China provides deep market penetration but may limit international growth opportunities available to larger rivals.